ScandiDos
ScandiDos is a Swedish medical technology company based in Uppsala that develops and sells measurement phantoms and quality-assurance systems for radiotherapy. Its products are used to verify treatment plans and dose delivery in cancer care, with sales handled directly in some markets and through distributors in others.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueHardware and software used to verify treatment plans and dose delivery in radiation therapy.
Physical phantom products used for calibration and verification in radiotherapy workflows.
Software platforms that support treatment-plan analysis and QA workflows.
Installation, maintenance, training, and technical support for installed systems.
Customers
ScandiDos sells to hospitals, cancer centers, and radiotherapy clinics that need to verify treatment plans and dose accuracy before patient treatment. It also serves public healthcare systems, private clinics, and foundation-owned institutions, often through local distributors in export markets. Customers buy the company’s systems to improve treatment safety, meet quality standards, and support advanced radiotherapy techniques.
Buy Delta4 systems and phantoms to verify radiotherapy plans and dose delivery before treatment.
Purchase QA equipment for standardized cancer-treatment workflows and compliance needs.
Buy verification systems to support precision radiotherapy and efficient patient throughput.
Resell ScandiDos products in markets where the company does not sell directly.
Strategy
ScandiDos focuses on radiotherapy quality assurance products that support precise and safe cancer treatment, with Delta4 Insight and newer stereotactic products extending the platform. The company’s commercial model combines direct sales in selected markets with distributors elsewhere, allowing it to reach installed radiotherapy centers globally. Its strategy also depends on product development, regulatory approvals, and maintaining relevance as radiotherapy techniques become more advanced.
Asian radiotherapy markets still require new equipment and offer more expansion than mature Western markets.
Western Europe and North America are mature, so growth depends on replacement sales and customer retention.
New products help the company stay relevant as radiotherapy techniques become more complex.
Regulatory clearance and distributor coverage are essential to selling in multiple countries.
Geography
ScandiDos is headquartered in Uppsala, Sweden, and its development and support functions are centered there. The company sells directly or through subsidiaries in the Nordics, France, and the United States, while a wider distributor network covers other markets, especially in Asia. The business is exposed to mature replacement demand in Western markets and to capital spending cycles in faster-growing Asian radiotherapy markets.
Risks
ScandiDos faces exposure to currency movements because much of its sales are invoiced in euros and U.S. dollars, and it also depends on key personnel and distributor relationships. As a medical technology company, it must navigate regulatory approvals and product-registration timelines, while the value of capitalized intangibles depends on successful commercialization of new products. The business is also exposed to the usual radiotherapy-market risks of long sales cycles, customer budget timing, and technology adoption.
- Impairment of capitalized intangiblesImpact: HighLikelihood: High
Delta4 Insight and other development assets depend on future commercialization success.
Exposure: Balance sheet valuation
- Foreign exchange volatilityImpact: HighLikelihood: Medium
Most sales are invoiced in euros and U.S. dollars, creating translation and transaction exposure.
Exposure: Revenue and cash flow
- Key-person dependenceImpact: High
The company relies on specialized technical and regulatory staff in a niche medtech business.
Exposure: Operations and product development
- Regulatory approval delaysImpact: High
Product registrations and renewals can take longer than planned in different countries.
Exposure: Launch timing and revenue recognition
- Distributor and partner concentrationImpact: Medium
Sales in many markets depend on local distributors and industry partners.
Exposure: Market access and sales continuity
Accounting
Judgemental itemsDelta4 Insight is in commercialization, so future cash flows drive whether capitalized assets remain recoverable.
Impact: Could accelerate write-downs if sales targets are missed
The company uses forward contracts to reduce currency volatility from euro and USD sales.
Impact: Can create gains/losses in other comprehensive income or P&L depending on hedge treatment
Sales may depend on delivery, installation, and regulatory clearance across multiple countries.
Impact: Quarterly revenue can shift with shipment and approval timing
The reports disclose intercompany purchases and management compensation.
Impact: Relevant for assessing transfer pricing and governance
Similar listed companies
Publicly listed companies with a comparable business focus.
Lantheus Holdings, Inc.
LNTH · In Vitro & In Vivo Diagnostic Substances
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
CareDx, Inc.
CDNA · Services-Medical Laboratories
Sedana Medical
SEDANA · Health Care
Sedana Medical is a Swedish company based in Danderyd that specializes in developing, manufacturing, and selling medical devices and pharmaceuticals.
Quarta-Rad, Inc.
QURT · Industrial Instruments For Measurement, Display, and Control
Scandi Standard
SCST · Consumer Staples
Scandi Standard is a leading producer of chicken-based products in the Nordic region, focusing on both ready-to-cook and ready-to-eat segments.
Last updated: 24/09/2026